|
Bristol Myers Squibb (BMS) announced the launch of Relopduo [fixed-dose combination (FDC) of nivolumab and relatlimab] in India following an approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services (DGHS), authorising its sale and distribution.
Relopduo is also India’s first LAG-3-based dual immunotherapy, representing an important scientific advancement in immuno-oncology and expanding treatment options for adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma.
Relopduo combines the PD-1 inhibitor nivolumab with the LAG-3-blocking antibody relatlimab in a fixed-dose combination regimen, simultaneously targeting two distinct immune checkpoints to help restore the body's immune response against cancer cells. In India, melanoma is often diagnosed late and includes aggressive subtypes such as mucosal melanoma, underscoring the need for timely access to innovative therapies and addressing a significant unmet need in the treatment of unresectable or metastatic melanoma.
“Advancing innovative immunotherapy approaches remains central to Bristol Myers Squibb’s mission of improving outcomes for patients with difficult-to-treat cancers,” said Dr. Ankita Jain, country medical director, Bristol Myers Squibb India. “The introduction of Relopduo brings a scientifically differentiated dual immunotherapy to eligible patients, offering new hope to those living with unresectable or metastatic melanoma. This launch also reflects our continued commitment to advancing immuno-oncology by bringing evidence-based, differentiated treatment options to India.”
The launch is supported by findings from the phase 2/3 RELATIVITY-047 study, which showed Relopduo increased median progression-free survival compared with nivolumab monotherapy (10.1 months vs. 4.6 months). Relopduo demonstrated a manageable safety profile consistent with the known mechanisms of action. Relopduo is an oncologist-prescribed treatment.
|